Cholestatic liver diseases: An era of emerging therapies

doi:10.12998/wjcc.v7.i13.1571

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9077)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

822

WORD

266

HTML

5500

Figures (1-2)

475

Tables (1-1)

285

Sum=7348

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

745

Download

984

Sum=1729

Jul 6, 2019 (publication date) through Feb 12, 2025

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. Jul 6, 2019; 7(13): 1571-1581
Published online Jul 6, 2019. doi: 10.12998/wjcc.v7.i13.1571

Full Size Figure Download Figure

Figure 2 Mechanism of action of Farnesoid X receptor ligands. FXR: Farnesoid X receptor; OCA: Obetocholic acid; BA: Bile acid; FGF: Fibroblast growth factor; OST: Organic solute transporter; BSEP: Bile-salt export pump.

Citation: Samant H, Manatsathit W, Dies D, Shokouh-Amiri H, Zibari G, Boktor M, Alexander JS. Cholestatic liver diseases: An era of emerging therapies. World J Clin Cases 2019; 7(13): 1571-1581
URL: https://www.wjgnet.com/2307-8960/full/v7/i13/1571.htm
DOI: https://dx.doi.org/10.12998/wjcc.v7.i13.1571